Literature DB >> 20434921

Future of local bone regeneration - Protein versus gene therapy.

J Fischer1, A Kolk, St Wolfart, C Pautke, P H Warnke, C Plank, R Smeets.   

Abstract

The most promising attempts to achieve bone regeneration artificially are based on the application of mediators such as bone morphogenetic proteins (BMPs) directly to the deficient tissue site. BMPs, as promoters of the regenerative process, have the ability to induce de novo bone formation in various tissues, and many animal models have demonstrated their high potential for ectopic and orthotopic bone formation. However, the biological activity of the soluble factors that promote bone formation in vivo is limited by diffusion and degradation, leading to a short half-life. Local delivery remains a problem in clinical applications. Several materials, including hydroxyapatite, tricalcium phosphate, demineralised bone matrices, poly-lactic acid homo- and heterodimers, and collagen have been tested as carriers and delivery systems for these factors in a sustained and appropriate manner. Unfortunately these delivery vehicles often have limitations in terms of biodegradability, inflammatory and immunological rejection, disease transmission, and most importantly, an inability to provide a sustained, continuous release of these factors at the region of interest. In coping with these problems, new approaches have been established: genes encoding these growth factor proteins can be delivered to the target cells. In this way the transfected cells serve as local "bioreactors", as they express the exogenous genes and secrete the synthesised proteins into their vicinity. The purpose of this review is to present the different methods of gene versus growth factor delivery in tissue engineering. Our review focuses on these promising and innovative methods that are defined as regional gene therapy and provide an alternative to the direct application of growth factors. Various advantages and disadvantages of non-viral and viral vectors are discussed. This review identifies potential candidate genes and target cells, and in vivo as well as ex vivo approaches for cell transduction and transfection. In explaining the biological basis, this paper also refers to current experimental and clinical applications.
Copyright © 2010 European Association for Cranio-Maxillo-Facial Surgery. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20434921     DOI: 10.1016/j.jcms.2010.03.016

Source DB:  PubMed          Journal:  J Craniomaxillofac Surg        ISSN: 1010-5182            Impact factor:   2.078


  24 in total

Review 1.  Strategies for controlled delivery of growth factors and cells for bone regeneration.

Authors:  Tiffany N Vo; F Kurtis Kasper; Antonios G Mikos
Journal:  Adv Drug Deliv Rev       Date:  2012-02-04       Impact factor: 15.470

Review 2.  Gene therapy approaches to regenerating bone.

Authors:  Nadav Kimelman Bleich; Ilan Kallai; Jay R Lieberman; Edward M Schwarz; Gadi Pelled; Dan Gazit
Journal:  Adv Drug Deliv Rev       Date:  2012-03-10       Impact factor: 15.470

Review 3.  Controlled release strategies for bone, cartilage, and osteochondral engineering--Part I: recapitulation of native tissue healing and variables for the design of delivery systems.

Authors:  Vítor E Santo; Manuela E Gomes; João F Mano; Rui L Reis
Journal:  Tissue Eng Part B Rev       Date:  2013-02-19       Impact factor: 6.389

Review 4.  Recent advances in bone tissue engineering scaffolds.

Authors:  Susmita Bose; Mangal Roy; Amit Bandyopadhyay
Journal:  Trends Biotechnol       Date:  2012-08-30       Impact factor: 19.536

Review 5.  Tissue engineering for bone regeneration and osseointegration in the oral cavity.

Authors:  Sophia P Pilipchuk; Alexandra B Plonka; Alberto Monje; Andrei D Taut; Alejandro Lanis; Benjamin Kang; William V Giannobile
Journal:  Dent Mater       Date:  2015-02-18       Impact factor: 5.304

6.  Multifunctional nanoparticles for intracellular drug delivery and photoacoustic imaging of mesenchymal stem cells.

Authors:  Isaac M Adjei; Hao Yang; Glendon Plumton; Lorena Maldonado-Camargo; Jon Dobson; Carlos Rinaldi; Huabei Jiang; Blanka Sharma
Journal:  Drug Deliv Transl Res       Date:  2019-06       Impact factor: 4.617

Review 7.  Growth factors and platelet-rich plasma: promising biological strategies for early intervertebral disc degeneration.

Authors:  Shan-zheng Wang; Qing Chang; Jun Lu; Chen Wang
Journal:  Int Orthop       Date:  2015-02-05       Impact factor: 3.075

8.  Angiopoietin-1 peptide QHREDGS promotes osteoblast differentiation, bone matrix deposition and mineralization on biomedical materials.

Authors:  Nicole Feric; Calvin C H Cheng; M Cynthia Goh; Vyacheslav Dudnyk; Val Di Tizio; Milica Radisic
Journal:  Biomater Sci       Date:  2014-10-01       Impact factor: 6.843

9.  Evaluation of fibrin-based gene-activated matrices for BMP2/7 plasmid codelivery in a rat nonunion model.

Authors:  Martin Kaipel; Sebastian Schützenberger; Anna T Hofmann; James Ferguson; Thomas Nau; Heinz Redl; Georg A Feichtinger
Journal:  Int Orthop       Date:  2014-09-06       Impact factor: 3.075

Review 10.  Emerging strategies in reprogramming and enhancing the fate of mesenchymal stem cells for bone and cartilage tissue engineering.

Authors:  Yu Seon Kim; Antonios G Mikos
Journal:  J Control Release       Date:  2020-12-31       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.